On May 10, 2012, the House Energy and Commerce Committee unanimously approved H.R. 5651, the Food and Drug Administration Reform Act. The legislation would reauthorize the Prescription Drug User Fee Act and the Medical Device User Fee Act, and it authorizes user fee programs for generic drugs and biosimilars. As part of the drug and device user fee reauthorization process, the FDA would commit to certain performance goals and to fostering more interaction, predictability, and certainty between industry and FDA. In addition, the bill: permanently authorizes the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act; makes a variety of FDA administrative reforms (including changes to the guidance process and conflict of interest rules); make various reforms to the medical device and drug review processes; and take steps intended to alleviate drug shortages. On April 25, the Senate Health, Education, Labor and Pensions (HELP) Committee also approved bipartisan legislation, the Food and Drug Administration Safety and Innovation Act, to authorize FDA user fees and address drug supply chain and drug shortage issues.